1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening
(
- Contribution to journal › Article
-
Mark
NATION-WIDE POPULATION-BASED STUDY ON 15-YEAR MORTALITY IN PROSTATE CANCER ACCORDING TO RISK CATEGORIES IN THE NATIONAL PROSTATE CANCER REGISTER (NPCR) OF SWEDEN
2011) 26th Annual Congress of the European Association of Urology In European Urology Supplements 10(2). p.324-325(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA
2009) 45th Annual Meeting of the American-Society-of-Clinical-Oncology In Journal of Clinical Oncology 27(15).(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Geographical variation in incidence of prostate cancer in Sweden - Survey from the National Prostate Cancer Register
(
- Contribution to journal › Article
- 2004
-
Mark
Lead time associated with screening for prostate cancer
(
- Contribution to journal › Article
- 2001
-
Mark
Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level
(
- Contribution to journal › Article
- 1999
-
Mark
Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL
(
- Contribution to journal › Article